Reportlinker Adds Global Biosimilars (Follow-on biologics) Market: An Analysis

NEW YORK, Nov. 18, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Biosimilars (Follow-on biologics) Market: An Analysis

http://www.reportlinker.com/p0330557/Global-Biosimilars-Follow-on-biologics-Market-An-Analysis.html

Biosimilars or FOBs (Follow-on biologics) refer to generic versions of patented branded biological drugs, developed subsequent to the patent expiry of brand name products. The biosimilars market is segmented into peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. In 2009, biosimilar recombinant non glycosylated protein products formed the largest market segment since blockbuster biopharmaceutical drug such as interferon, human growth hormone-Somatropin, insulin and G-CSF; belong to this class and have wide range of applications.

Overburdened due to rising healthcare costs, ageing population, expensive drugs and pharmaceutical expenditure, biosimilar market is getting boost from increasing user acceptance and emerging Indian and Chinese markets. The major challenge for the biosimilar market is risk involved with the high investment and possible failure of the drug during development stages. However, opportunities for biosimilar market is immense, as biologics are going to be off patent by 2015 and an anticipated approval pathway in U.S. will open up potentially largest market. The growth potential of the biosimilars market is expected to be strong, with patents for a number of second-generation therapeutic proteins (Enbrel, Remicade, Herceptin, etc.) slated for expiry between 2013 and 2019. The global biosimilars market is highly fragmented with the presence of some leading players such as Biocon, Dr Reddy's Lab, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt.

The report titled "Global Biosimilars (Follow-on biologics) Market: An Analysis" covers the overview, market size and segmentation of the biosimilars market. The various drivers and the challenges faced by the market are also discussed in detail. The competitive aspect of the market is also highlighted and the key players are profiled with their strategies for this market.

1. Global Biopharmaceutical Market

2. Global Biosimilars Market

2.1 Overview

2.2 Market Size

2.3 Geographical Segmentation

2.4 Currently Marketed Biosimilars

2.4.1 Erythropoietin

2.4.2 Human Growth Hormone

2.4.3 Filgrastim

3. Market Drivers

3.1 Rising Healthcare Costs

3.2 Large Number of Blockbuster Biologics Slated for Patent Expiry

3.3 Leading Generics Players Spearheading Development

3.4 Rise in Ageing Population

3.5 Cost Effective Option for Pharmaceutical Companies

4. Market Constraints

4.1 Regulatory Restrictions and Hurdles

4.2 High Development Costs 24

4.3 Manufacturing Complexities

5. Opportunities

5.1 Burgeoning Indian and Chinese Market

5.2 Monoclonal Antibodies- Fastest Growing segment

6. Market Outlook

7. Major Players

7.1 Teva Pharmaceuticals Industries Ltd.

7.1.1 Business Description

7.1.2 Business Strategies

7.2 Biocon

7.2.1 Business Description

7.2.2 Business Strategies

7.3 Hospira Inc.

7.3.1 Business Description

7.3.2 Business Strategies

Charts and Figures

Biopharmaceutical Value Chain

Global Biopharmaceutical Market (2004-2009)

Global Biopharmaceutical Market by Product (2009)

Categories of Biosimilars Market

Biosimilars Development Process

Difference between Small Molecule Generics and Biosimilars

Global Biosimilar Market Revenue (2008-2014F)

Global Biosimilars Market by Product (2009)

Global Market Potential for Biosimilars in Different Categories (2009)

Major Blockbuster biologics whose patents will expire from 2012- 2019

Marketed Biosimilars by Product Group

Total Healthcare Expenditure Per Capita in Selected Developed Countries (2008)

Real Annual Growth in per Capita Health Spending (%): 2000-2008

Potential Market Potential for Biosimilars

Leading Players in Biosimilars market and Products in Pipeline

Ageing Population Worldwide (age>65) 2005-2015F

Cost Comparison of Biosimilars and Innovator Biologics

Biosimilar Approval in EU

Indian Biosimilars Market Revenue (2008-2012F)

India's Biosimilar Market Breakdown (2009)

Potential Global Market for Biosimilars (2008-2015)

Number of Biologics Scheduled to Go-off Patent (2008-2015)

Annual Revenues of Teva Pharmaceuticals (2005-2009)

Annual Revenues of Biocon (FY 06-FY 10)

Annual Revenues of Hospira Inc. (2009)

To order this report:

Biotechnology Industry: Global Biosimilars (Follow-on biologics) Market: An Analysis

Biotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT:

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805) 652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.